Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer

被引：0
|
作者：
Tan, W. L. [1 ]
Tan, S. H. [1 ]
Tan, D. S. W. [1 ]
Lai, G. G. Y. [1 ]
Ang, M. -K. [1 ]
Jain, A. [1 ]
Kanesvaran, R. [1 ]
Rajasekaran, T. [1 ]
Saw, S. P. L. [1 ]
Teh, Y. L. [1 ]
Chan, J. [1 ]
Ng, Q. S. [1 ]
Lim, D. W. -T. [1 ]
机构：
[1] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
EGFR-mutated NSCLC; First-line Osimertinib; Asian patients;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-31
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [21] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Ying Cheng
    Yong He
    Wei Li
    He-long Zhang
    Qing Zhou
    Buhai Wang
    Chunling Liu
    Andrew Walding
    Matilde Saggese
    Xiangning Huang
    Minhao Fan
    Jia Wang
    Suresh S. Ramalingam
    Targeted Oncology, 2021, 16 : 165 - 176
  • [22] First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study - interim analysis)
    Breadner, D. A.
    Liu, G.
    Rothenstein, J.
    Verma, S.
    Menjak, I.
    Cheema, P. K.
    Juergens, R.
    Mithoowani, H.
    Bains, P.
    Wang, Y.
    Wheatley-Price, P.
    Vincent, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [23] Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
    Shu, Yamin
    Ding, Yufeng
    He, Xucheng
    Liu, Yanxin
    Wu, Pan
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [24] First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
    Nie, Naifu
    Li, Jianghua
    Zhang, Jian
    Dai, Jie
    Liu, Zhulin
    Ding, Zhenyu
    Wang, Yubo
    Zhu, Mengxiao
    Hu, Chen
    Han, Rui
    Tang, Huan
    Li, Li
    He, Yong
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [25] Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1690
  • [26] Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
    Hori, Tomoki
    Yamamoto, Kazuhiro
    Ito, Takefumi
    Ikushima, Shigeki
    Omura, Tomohiro
    Yano, Ikuko
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 281 - 288
  • [27] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
    Soria, J. -C.
    Ohe, Y.
    Vansteenkiste, J.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Imamura, F.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cho, B. C.
    Cheng, Y.
    Cho, E. K.
    Voon, P. J.
    Planchard, D.
    Su, W. -C.
    Gray, J. E.
    Lee, S. -M.
    Hodge, R.
    Marotti, M.
    Rukazenkov, Y.
    Ramalingam, S. S.
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 113 - 125
  • [28] First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
    Nie, Naifu
    Li, Jianghua
    Zhang, Jian
    Dai, Jie
    Liu, Zhulin
    Ding, Zhenyu
    Wang, Yubo
    Zhu, Mengxiao
    Hu, Chen
    Han, Rui
    Tang, Huan
    Li, Li
    He, Yong
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [29] A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib.
    Viray, Hollis
    Piper-Vallillo, Andrew
    Widick, Page
    Academia, Emmeline
    Shea, Meghan
    Rangachari, Deepa
    Costa, Daniel Botelho
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Autopsy and Next Generation Sequencing Report of First-Line Treatment with Osimertinib for EGFR-Mutated Squamous Cell Carcinoma of the Lung
    Nishimura, T.
    Fujiwara, T.
    Fujimoto, H.
    Ibata, H.
    Gabazza, E. C.
    Kobayashi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S653 - S654
12345